Champix: A Clinically Proven Aid to Quit Smoking for Good
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 28 | $4.42 | $123.84 (0%) | 🛒 Add to cart |
| 56 | $3.84 | $247.68 $215.00 (13%) | 🛒 Add to cart |
| 84 | $3.57
Best per pill | $371.52 $300.14 (19%) | 🛒 Add to cart |
Synonyms | |||
Champix (varenicline) is a prescription medication specifically designed to assist adults in quitting smoking. It functions as a partial agonist, selectively targeting α4β2 nicotinal acetylcholine receptors in the brain to reduce both the severity of nicotine withdrawal symptoms and the rewarding sensations associated with smoking. By mitigating cravings and diminishing the pleasure derived from cigarettes, Champix supports a structured smoking cessation journey, significantly increasing the likelihood of long-term abstinence when used as part of a comprehensive quit plan that includes behavioral support.
Features
- Active ingredient: Varenicline (as varenicline tartrate)
- Pharmaceutical form: Film-coated tablets (0.5 mg and 1 mg)
- Mechanism: Partial agonist at α4β2 nicotinic acetylcholine receptors
- Treatment duration: Standard 12-week course, with option for additional 12 weeks for sustained abstinence
- Prescription-only medication requiring medical consultation
- Pack sizes: Starting pack (includes titration doses) and continuing pack
Benefits
- Significantly reduces the urge to smoke by alleviating nicotine cravings
- Diminishes the satisfaction derived from smoking if a cigarette is smoked, helping break the habit
- Doubles the chances of long-term smoking cessation compared to willpower alone
- Provides a structured, phased treatment regimen to support the quitting process
- Non-nicotine based therapy, avoiding continued nicotine exposure
- Supported by extensive clinical trial data demonstrating efficacy and safety
Common use
Champix is indicated for smoking cessation in adults. It is intended for use as part of a comprehensive quit attempt that includes motivational support, counseling, and behavioral strategies. Treatment should be initiated while the patient is still smoking, with a target quit date set between day 8 and day 14 of treatment. The medication is suitable for most adult smokers motivated to quit, regardless of smoking history or number of previous quit attempts.
Dosage and direction
Dosage regimen:
- Days 1–3: 0.5 mg once daily
- Days 4–7: 0.5 mg twice daily
- Day 8 to end of treatment: 1 mg twice daily
Administration:
- Take after food with a full glass of water to reduce potential nausea
- Do not crush, chew, or break tablets; swallow whole
- Continue treatment for 12 weeks; patients who have successfully stopped smoking may benefit from an additional 12-week course to maintain abstinence
- For patients with severe renal impairment (CrCL <30 mL/min), maximum dose is 0.5 mg twice daily
Precautions
- Monitor patients for changes in behavior, hostility, agitation, depressed mood, and suicide-related events; discontinue treatment if such symptoms develop
- Use with caution in patients with history of psychiatric illness
- Dose reduction or discontinuation may be necessary if nausea is troublesome and persistent
- Not recommended during pregnancy; women of childbearing potential should use effective contraception
- Use with caution in elderly patients due to potential for reduced renal function
- May cause dizziness and somnolence; caution advised when driving or operating machinery
Contraindications
- Hypersensitivity to varenicline or any excipients
- End-stage renal disease
- Severe renal impairment (unless dose-adjusted under close supervision)
- Not recommended in patients under 18 years of age
- Should not be used concurrently with other smoking cessation therapies unless specifically advised by a healthcare professional
Possible side effects
Very common (≥1/10):
- Nausea
- Insomnia
- Abnormal dreams
- Headache
Common (≥1/100 to <1/10):
- Increased appetite
- Somnolence
- Dizziness
- Dysgeusia (taste disturbance)
- Vomiting
- Constipation
- Diarrhea
- Dry mouth
- Dyspepsia
- Flatulence
- Irritability
- Anxiety
- Depression
- Emotional lability
- Agitation
- Sleep disorder
- Fatigue
- Malaise
Uncommon (≥1/1,000 to <1/100):
- Suicidal ideation
- Hostility
- Aggression
- Tachycardia
- Hypertension
- Hypersensitivity reactions
- Seizures
- Renal impairment
Drug interaction
- No clinically significant pharmacokinetic interactions with smoking cessation aids, antidepressants, or theophylline
- Potential additive effects with alcohol; some patients reported increased intoxication, aggressive behavior, or amnesia
- Use with caution with drugs that are primarily renally excreted
- May require dose adjustment when co-administered with cimetidine (increases varenicline exposure by 29%)
- No interaction observed with warfarin; however, monitoring INR is recommended after smoking cessation
Missed dose
- If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose
- Do not take a double dose to make up for a missed dose
- Resume regular dosing schedule with the next dose
- If multiple doses are missed, consult healthcare provider for guidance on resuming treatment
Overdose
- Cases of overdose have reported nausea, vomiting, drowsiness, tachycardia, and disorientation
- Supportive care is recommended, including monitoring of vital signs and ECG
- Hemodialysis is effective in removing varenicline (approximately 80% removed over 4 hours)
- There is no specific antidote; treatment should be symptomatic and supportive
- Contact poison control center or emergency department immediately if overdose is suspected
Storage
- Store below 30°C (86°F)
- Keep in original packaging to protect from light and moisture
- Keep out of sight and reach of children
- Do not use after the expiration date printed on the packaging
- Dispose of unused medication properly according to local regulations
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Champix is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will achieve smoking cessation. Patients should discuss their medical history, current medications, and treatment goals with their healthcare provider before starting Champix. The full prescribing information should be consulted before initiation of therapy.
Reviews
Clinical studies demonstrate that Champix significantly improves smoking cessation rates compared to placebo and bupropion. In randomized controlled trials, continuous abstinence rates at 9-52 weeks were approximately 22% for Champix versus 8-16% for placebo. Many patients report reduced cravings and easier transition to smoke-free living, though individual experiences with side effects vary. Healthcare professionals generally regard Champix as an effective option within comprehensive smoking cessation programs, particularly for motivated patients who have struggled with previous quit attempts.